Diamonds and Dogs

12/7/17

Sage Therapeutics (SAGE) looks wise. The drug company's stock is up 75% just today thanks to positive mid-stage study results for their depression drug. The 89-patient study testing the drug, SAGE-217, showed statistically significant reduction of depression symptoms, when compared to a placebo. Depression is a common mental illness characterized by persistent sadness and a loss of interest and lack of ability to do everyday activities and work. The drug was granted fast-track designation by the U.S. Food and Drug Administration in back in May.

Lending Club (LC) may need a loan of their own. The financial company is down 14% to a new low after lowering its outlook for the fourth quarter and delivering a lower-than-expected forecast for next year. The stock is down 40% since October and down 85% since coming public at the end of 2014. Not a bright future for Lending Club.